A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2,600
- 试验地点
- 1
- 主要终点
- To compare the pCR rates of neoadjuvant treatment in all 3 Settings
研究概览
简要总结
Anthracycline-taxane based chemotherapy regimens are recommended mainly by current guidelines for neoadjuvant application of systemic treatment. The addition of other cytotoxic agents, e.g. antimetabolites, vincaalkaloids, or platinum salts resulted in marginal increase in efficacy, but was associated also with an increase in toxicity. Recently, only the addition of the Her-2 antibody trastuzumab has significantly improved pathologic response rate.
Therefore, two major strategies are followed in current research projects:
- To improve the selection of patients according to their tumors' sensitivity to chemotherapy.
- To implement small molecules with specific mechanism of action.
Within the GeparQuinto trial, the first strategy is followed by:
- The PREDICT substudy. A gene signature specific for the response to anthracyclines and taxanes will be prospectively evaluated for its ability to identify patients with chance higher than 50% for a pCR. The results may leed to a better risk-benefit ratio for the use of conventional chemotherapy.
- Adapting further chemotherapy to the response of the tumor to the first couple of chemotherapy cycles. Based on the previous experience made by the GeparTrio study, patients not responding early have a low chance to respond with a pCR irrespective of the type of chemotherapy. So, if further chemotherapy is planned, therapy should be selected according to a favorable toxicity profile.
The second strategy is followed by investigating in three parallel group comparisons the efficiency of three distinct small molecules which appear to be generally active in breast cancer:
- Bevacizumab, an inhibitor of the VEGF pathway targeting tumor neo-angiogenesis.
- Lapatinib, an inhibitor of the Her-1 and Her-2 receptor tyrosine kinase.
- RAD001 (Everolimus), an inhibitor of the mTOR molecule, a central controller of tumor cell growth and angiogenesis and chemosensitizer.
Treatment for patients participating in the GeparQuinto study will be allocated according to the Her-2 status of the tumor as well as according to the sonographic response after the first 4 cycles of treatment. Experimental therapy with bevacizumab, lapatinib, and everolimus (RAD001) will be randomly added in distinct settings.
详细描述
Primary objectives:
To compare the pCR rates of neoadjuvant treatment of epirubicin / cyclophosphamide followed by docetaxel (EC-T) with or without bevacizumab (EC-T vs. ECB-TB) in patients with Her-2 negative primary breast cancer (Setting I).
To compare the pCR rates of neoadjuvant treatment with weekly paclitaxel with or without Everolimus (RAD001) (Pw vs. PwR) in patients with Her-2 negative primary breast cancer showing no sonographic response to 4 cycles of EC +/-B (Setting II).
To compare the pCR rates of neoadjuvant treatment with epirubicin / cyclophosphamide followed by docetaxel with either trastuzumab or lapatinib (ECH-TH vs. ECL-TL) in patients with Her-2 positive primary breast cancer (Setting III).
Secondary objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Complete baseline documentation sent to GBG Forschungs GmbH;
- •Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration is not sufficient. Incisional biopsy is not allowed.
- •Tumor lesion in the breast with a palpable size of ≥ 2 cm or a sonographically size of at least 1 cm in maximum diameter. The lesion has to be measurable in two-dimensions preferably by sonography. In case of inflammatory disease the extent of inflammation can be used as measurable lesion;
- •Patients should have stages of disease in which adjuvant chemotherapy would be considered.
- •Locally advanced tumors with cT4 or cT3 or
- •Estrogen (ER)- and progesterone (PgR)-receptor negative tumors or
- •ER or PgR positive tumors which are cN+ (for cT2) or pNSLN+ (for cT1) * During the Run-In-Safety phase only patients with cT4 or cT3 cN+ disease are eligible.
- •Known HER-2/neu status detected on core biopsy. HER-2/neu positive is defined as HercepTest IHC 3+ or FISH+;
- •Age older than 18 years;
- •Karnofsky Performance status index at least 80%;
- •Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 1 month prior to registration.
- •Laboratory requirements:
- •Hematology: Absolute neutrophil count (ANC) ≥ 2.0 x 10e9/L platelets ≥ 100 x 10e9/L, Hemoglobin ≥ 10 g/dL (≥ 6.2 mmol/L) Hepatic function: Total bilirubin < 1 x UNL ASAT (SGOT) and ALAT (SGPT)≤ 2.5 x UNL Alkaline phosphatase ≤ 5 UNL. Patients with ASAT and / or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study; Renal function: Creatinine ≤ 175 µmol/L (2 mg/dL) < 1,25 UNL (or the calculated creatinine clearance ≥ 60 mL/min) Urine dipstick for proteinuria < 2+. Patients discovered to have ≥2+ proteinuria on dipstick urinalysis should undergo a 24 hour urine collection and must demonstrate ≤1 g of protein in 24 hours
- •Paraffin tumor tissue block and two serum samples centrally made available
- •Negative pregnancy test (urine or serum)
- •Complete staging work-up within 3 months prior to registration.
- •Patients must be available and compliant for treatment and follow-up.
- •Exclusion criteria:
- •Patients with low or moderate risk, which are only doubtful candidates for adjuvant chemotherapy
- •Evidence of distant metastasis;
- •Prior chemotherapy for any malignancy;
- •Prior radiation therapy for breast cancer;
- •Pregnant or lactating patients.
- •Inadequate general condition
- •Previous malignant disease
- •Known or suspected congestive heart failure (>NYHA I) and/or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension, rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease
- •Previous thromboembolic event
- •Known hemorrhagic diathesis or increased bleeding risk
- •History of significant neurological or psychiatric disorders that would prohibit the understanding and giving of informed consent;
- •Pre-existing motor or sensory neuropathy of a severity more than grade 2 by NCI criteria
- •Currently active infection;incomplete wound healing
- •Active peptic ulcer
- •Disease significantly affecting gastrointestinal function
- •History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrollment
- •Severe pulmonary condition/illness
- •Unstable diabetes mellitus; insulin dependent type II diabetes mellitus
- •Major surgery or incomplete wound healing within the last 28 days
- •Definite contraindications for the use of corticosteroids
- •Known hypersensitivity reaction to one of the investigational compounds or incorporated substances; or known dihydropyrimidine dehydrogenase deficiency
- •Concurrent treatment with:chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (20 mg methylprednisolone or equivalent); sex hormones.Virostatic agents like sorivudine or analogs like brivudine, concurrent treatment with aminoglycosides; anticoagulants: heparin, warfarin as well as acetic acid (e.g. Aspirin®) at a dose of > 325mg/day or clopidogrel at a dose of > 75 mg/day)e.other experimental drugs or any other anti-cancer therapy; drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (e.g. Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, Telithromycin, Erythromycin, Verapamil, Dilitazem, within the last 5 days or the expected need for these treatments during study participation.
排除标准
- 未提供
研究组 & 干预措施
1
EC-T
干预措施: epirubicin - cyclophosphamide / docetaxel (Drug)
2
EC-T +/- B
干预措施: epirubicin - cyclophosphamide / docetaxel + bevacizumab (Drug)
3
Pw
干预措施: paclitaxel (Drug)
4
Pw + RAD001
干预措施: paclitaxel + everolimus (RAD001) (Drug)
5
EC-T + H
干预措施: epirubicin - cyclophosphamide / docetaxel + trastuzumab (Drug)
6
EC-T + L
干预措施: epirubicin - cyclophosphamide / docetaxel + lapatinib (Drug)
结局指标
主要结局
To compare the pCR rates of neoadjuvant treatment in all 3 Settings
时间窗: 2009
次要结局
- To determine the breast conservation rate after each treatment.(2009)
- To assess the toxicity of and compliance to all six treatments.(2009)
- To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.(2012)
- To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)(2009)
- To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy(2012)